Breaking News, Collaborations & Alliances

Amgen, Servier Enter CV Collaboration

Exchange U.S. and EU product development options

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen and Servier have entered a new R&D collaboration in cardiovascular disease. Amgen has obtained U.S. commercial rights to Servier’s oral drug, approved in the EU as Procoralan (ivabradine), for chronic heart failure and stable angina in patients with elevated heart rates, as well as an exclusive option to develop and commercialize Servier’s investigational molecule, S38844, currently in Phase II development for the treatment of heart failure.   Additionally, Servier has obta...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters